Cervical Intraepithelial Neoplasia
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
City TherapeuticsMA - Cambridge
1 programRecombinant Human Papillomavirus BivalentN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Biotest PharmaceuticalsSOR007
Eli Lilly and CompanyPemetrexed
City TherapeuticsRecombinant Human Papillomavirus Bivalent
Clinical Trials (3)
Total enrollment: 29 patients across 3 trials
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
Start: Oct 2017Est. completion: Mar 2019
Phase 2Withdrawn
A Trial for Patients With Advanced/Recurrent Cervical Cancer
Start: Feb 2005Est. completion: Oct 200729 patients
Phase 2Completed
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
Start: Feb 2024Est. completion: Dec 2026
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space